Evidence map›Paper›PMID 33598692›Full record

ArticleBlood2021

Factor XII plays a pathogenic role in organ failure and death in baboons challenged with Staphylococcus aureus.

Robert Silasi, Ravi S Keshari, Girija Regmi, Cristina Lupu, Constantin Georgescu, Joe H Simmons, Michael Wallisch, Tia C L Kohs, Joseph J Shatzel, Sven R Olson and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Factor XII-A New Therapeutic Target? A Systematic Review.International journal of molecular sciences · 2026
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Therapeutic Potential of C1-Inhibitor in Vascular Diseases and Beyond.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Factor XII-driven coagulation traps bacterial infections.The Journal of experimental medicine · 2025
    Article
  11. Circulation research · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Robert SilasiCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.ORCID 0000-0001-9590-6160
Ravi S KeshariCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.ORCID 0000-0002-4177-9095
Girija RegmiCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.ORCID 0000-0001-6827-3783
Cristina LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.ORCID 0000-0001-8619-0893
Constantin GeorgescuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.
Joe H SimmonsMichale E. Keeling Center for Comparative Medicine and Research, University of Texas MD Anderson Cancer Center, Bastrop, TX.ORCID 0000-0003-1815-6831
Michael WallischDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0002-7133-795X
Tia C L KohsDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0002-7900-0016
Joseph J ShatzelDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.
Sven R OlsonDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0002-2717-4620
Christina U LorentzDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0002-6885-2352
Cristina PuyDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0002-5911-8156
Erik I TuckerDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.
David GailaniDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-8142-8014
Sidney StricklandPatricia and John Rosenwald Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY; and.ORCID 0000-0002-3072-9244
András GruberDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0001-6212-2247
Owen J T McCartyDepartment of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR.
Florea LupuCardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK.ORCID 0000-0003-1249-9278
Oregon Health & Science University · USOklahoma Medical Research Foundation · USRockefeller University · USThe University of Texas MD Anderson Cancer Center · USVanderbilt University Medical Center · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2M
Specific Pathogen Free Baboon Research Resource (SPFBRR) - Bridge Funding Administrative SupplementP40OD024628 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WILLIAM D HOPKINS · 2017 to 2026
$15.7M
Characterization of Coagulation Factor-platelet Interactions: Role of FXIR01HL101972 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Owen J McCarty · 2010 to 2026
$8.5M
Pilot ProjectP30GM114731 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MCEVER, RODGER PAUL · 2016 to 2020
$6.5M
Biochemistry and Pathophysiology of Factor XI and Contact ActivationR35HL140025 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GAILANI, DAVID · 2018 to 2024
$5.5M
Factor XI inhibitor for thrombosisR44HL106919 · NHLBI · ARONORA, INC. · PI LORENTZ, CHRISTINA U, TUCKER, ERIK IAN · 2012 to 2019
$5.0M
Contact Activation and InfectionR01AI157037 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2020 to 2024
$3.3M
Therapeutic factor XI blockade for sepsisR44AI088937 · NIAID · ARONORA, INC. · PI GRUBER, ANDRAS, TUCKER, ERIK IAN · 2012 to 2014
$3.0M
Therapeutic factor XI blockade for sepsisR44HL128016 · NHLBI · ARONORA, INC. · PI GRUBER, ANDRAS, TUCKER, ERIK IAN · 2015 to 2017
$2.4M
FXI and SepsisR01GM116184 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2015 to 2018
$1.9M
Coagulation and Complement Activation in SepsisR01GM121601 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI LUPU, FLOREA · 2017 to 2020
$1.6M
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.R01HL151367 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SHATZEL, JOSEPH JAMES · 2020 to 2024
$1.5M
NHLBI NIH HHS R01 HL101972NHLBI NIH HHS R01 HL151367NHLBI NIH HHS R35 HL140025NHLBI NIH HHS R43 HL106919NHLBI NIH HHS R44 HL106919NHLBI NIH HHS R44 HL128016NIAID NIH HHS R01 AI157037NIAID NIH HHS R43 AI088937NIAID NIH HHS R44 AI088937NIAID NIH HHS U19 AI062629NIGMS NIH HHS P30 GM114731NIGMS NIH HHS R01 GM116184NIGMS NIH HHS R01 GM121601NIGMS NIH HHS R01 GM122775NIH HHS P40 OD024628
6 · The paper itself

Abstract

Activation of coagulation factor (F) XI promotes multiorgan failure in rodent models of sepsis and in a baboon model of lethal systemic inflammation induced by infusion of heat-inactivated Staphylococcus aureus. Here we used the anticoagulant FXII-neutralizing antibody 5C12 to verify the mechanistic role of FXII in this baboon model. Compared with untreated control animals, repeated 5C12 administration before and at 8 and 24 hours after bacterial challenge prevented the dramatic increase in circulating complexes of contact system enzymes FXIIa, FXIa, and kallikrein with antithrombin or C1 inhibitor, and prevented cleavage and consumption of high-molecular-weight kininogen. Activation of several coagulation factors and fibrinolytic enzymes was also prevented. D-dimer levels exhibited a profound increase in the untreated animals but not in the treated animals. The antibody also blocked the increase in plasma biomarkers of inflammation and cell damage, including tumor necrosis factor, interleukin (IL)-1β, IL-6, IL-8, IL-10, granulocyte-macrophage colony-stimulating factor, nucleosomes, and myeloperoxidase. Based on clinical presentation and circulating biomarkers, inhibition of FXII prevented fever, terminal hypotension, respiratory distress, and multiorgan failure. All animals receiving 5C12 had milder and transient clinical symptoms and were asymptomatic at day 7, whereas untreated control animals suffered irreversible multiorgan failure and had to be euthanized within 2 days after the bacterial challenge. This study confirms and extends our previous finding that at least 2 enzymes of the contact activation complex, FXIa and FXIIa, play critical roles in the development of an acute and terminal inflammatory response in baboons challenged with heat-inactivated S aureus.

Indexed as

AnimalsAntibodiesBlood Coagulation DisordersBlood PlateletsCellular MicroenvironmentComplement ActivationFactor XIIFemaleFibrinogenHot TemperatureInflammationMaleMultiple Organ FailurePapioStaphylococcal InfectionsStaphylococcus aureusAntibodiesFactor XIIFibrinogen

Identifiers

PMID33598692
PMCPMC8288658
OpenAlexW3130527264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.